Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
OwnerJoachim Hauber, Alexander Thorsten Prechtelinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell as well as pharmaceutical compositions comprising such compounds and methods for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins.
Claims31
A compound that specifically blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduces expression of a member of the CD83 family of proteins in a cell.
A compound according to any of the preceding claims, characterized in that the compound contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof.
A compound according to any of the preceding claims, characterized in that the compound contains from nucleotide 466 to 618 of the sequence in SEQ ID NO:1 or a derivative thereof.
A compound according to any of the preceding claims, characterized in that the compound contains from nucleotide 466 to 615 of the sequence in SEQ ID NO:1 or a derivative thereof.
A compound according to any of the preceding claims, characterized in that the compound contains a nucleic acid having a secondary structure comprising a 3-pronged stem-loop structure with an energy of −28.4 kcal/mol or less, preferably −29.7 kcal/mol or less.
A compound according to any of the preceding claims, characterized in that the compound is a nucleic acid that comprises regulatory sequences that lead to the transcription of an RNA molecule from said nucleic acid in a cell.
A compound according to any of the preceding claims, characterized in that the compound is a nucleic acid that does not contain regulatory sequences that lead to the translation of a polypeptide or protein from said nucleic acid in a cell.
Method for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins comprising the steps of incubating one or more compounds in a reaction comprising:
- (a) a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and
- (b) a member of the ELAV superfamily of proteins or derivative thereof
- under conditions sufficient to allow the components to interact and determining whether the compound blocks the binding between the nucleic acid molecule and the member of the ELAV superfamily of proteins.
Use of a compound that blocks the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins when incubated in a reaction comprising:
- (a) a nucleic acid molecule that contains at least a portion of the coding region of a member of the CD83 family of proteins or a derivative thereof and
- (b) a member of the ELAV superfamily of proteins or derivative thereof
- under conditions sufficient to allow the components to interact, for the production of a pharmaceutical composition for treating or preventing disease involving the direct or indirect participation of DC.
Dependencies are inferred from the claim text.